Person-centred, integrated non-communicable disease and HIV decentralized drug distribution in Eswatini and South Africa: outcomes and challenges.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
07 2023
Historique:
received: 28 11 2022
accepted: 09 05 2023
medline: 7 7 2023
pubmed: 6 7 2023
entrez: 6 7 2023
Statut: ppublish

Résumé

Non-communicable diseases (NCDs) are highly prevalent in people living with HIV above 50 years of age and account for increasing mortality. There is little published evidence supporting person-centred, integrated models of HIV care, hypertension and diabetes treatment in southern Africa, and no data demonstrating mortality reduction. Where clinical visits for NCDs and HIV cannot be combined, integrated medication delivery presents an opportunity to streamline care and reduce patient costs. We present experiences of integrated HIV and NCD medication delivery in Eswatini and South Africa, focusing on programme successes and implementation challenges. Programmatic data from Eswatini's Community Health Commodities Distribution (CHCD) from April 2020 to December 2021 and South Africa's Central Chronic Medicines Dispensing and Distribution (CCMDD) from January 2016 to December 2021 were provided by programme managers and are summarized here. Launched in 2020, Eswatini's CHCD provides over 28,000 people with and without HIV with integrated services, including HIV testing, CD4 cell count testing, antiretroviral therapy refills, viral load monitoring and pre-exposure prophylaxis alongside NCD services, including blood pressure and glucose monitoring and hypertension and diabetes medication refills.  Communities designate neighbourhood care points and central gathering places for person-centred medication dispensing.  This programme reported fewer missed medication refill appointments among clients in community settings compared to facility-based settings. South Africa's CCMDD utilizes decentralized drug distribution to provide medications for over 2.9 million people, including those living with HIV, hypertension and diabetes.  CCMDD incorporates community-based pickup points, facility "fast lanes" and adherence clubs with public sector health facilities and private sector medication collection units.  There are no out-of-pocket payments for medications or testing commodities.  Wait-times for medication refills are lower at CCMDD sites than facility-based sites.  Innovations to reduce stigma include uniformly labelled medication packages for NCD and HIV medications. Eswatini and South Africa demonstrate person-centred models for HIV and NCD integration through decentralized drug distribution. This approach adapts medication delivery to serve individual needs and decongest centralized health facilities while efficiently delivering NCD care.  To bolster programme uptake, additional reporting of integrated decentralized drug distribution models should include HIV and NCD outcomes and mortality trends.

Identifiants

pubmed: 37408477
doi: 10.1002/jia2.26113
pmc: PMC10323318
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e26113

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2023 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

AIDS. 2018 Jul 1;32 Suppl 1:S33-S42
pubmed: 29952788
Int J Integr Care. 2022 Jan 31;22(1):6
pubmed: 35136387
BMJ Open. 2020 May 15;10(5):e035412
pubmed: 32414827
BMJ Open. 2021 Jul 12;11(7):e043705
pubmed: 34253658
PLOS Glob Public Health. 2022 Feb 3;2(2):e0000084
pubmed: 36962287
Clin Infect Dis. 2022 Sep 10;75(4):657-664
pubmed: 34864933
BMC Health Serv Res. 2021 May 17;21(1):463
pubmed: 34001123
AIDS. 2018 Mar 27;32(6):773-782
pubmed: 29369158
PLoS Med. 2021 Sep 23;18(9):e1003812
pubmed: 34555010
AIDS. 2018 Jul 1;32 Suppl 1:S5-S20
pubmed: 29952786
Lancet Glob Health. 2019 Oct;7(10):e1375-e1387
pubmed: 31537368
BMJ Open. 2020 Oct 7;10(10):e039237
pubmed: 33033029

Auteurs

Deborah Goldstein (D)

Office of HIV/AIDS, USAID, Washington, DC, USA.

Nathan Ford (N)

Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland.

Nicholas Kisyeri (N)

Eswatini National AIDS Program, Mbabane, Eswatini.
ICAP, Columbia University, Mbabane, Eswatini.

Maggie Munsamy (M)

National Department of Health, Pretoria, South Africa.

Lirica Nishimoto (L)

FHI 360, Durham, North Carolina, USA.

Kufor Osi (K)

Resolve to Save Lives, Abuja, Nigeria.

Herve Kambale (H)

ICAP, Columbia University Mailman School of Public Health, New York, New York, USA.

Thomas Minior (T)

Office of HIV/AIDS, USAID, Washington, DC, USA.

Moses Bateganya (M)

FHI 360, Durham, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH